Bionano Genomics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
By Karen Roman Prenetics Global Limited (Nasdaq: PRE) confirmed its multi-year partnership with #1 New York Times bestselling author and award-winning podcast host of On Purpose, Jay Shetty, making him […]
2026-05-16. The following slide deck was published by Bionano Genomics, Inc.
Moby summary of Bionano Genomics, Inc.'s Q1 2026 earnings call
Bionano Genomics Inc (BNGO) reports strong revenue growth and operational efficiencies, but faces supply constraints and leadership transitions.
Bionano Genomics (BNGO) delivered earnings and revenue surprises of +6.17% and +2.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics (NASDAQ:BNGO) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://edge.media-server.com/mmc/p/6tmtcpga/ Summary Bionano Genomics reported Q1 2026 revenue of $6.7 million, a 4% increase year-over-year, with flow cell sales up
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call May 13, 2026 4:30 PM EDTCompany ParticipantsAlbert Luderer - Chairman & Interim CEOMark Adamchak -...
Presentation Operator MessageOperator Good day, and welcome to the Bionano First Quarter 2026 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the...
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.95) by 20 percent. This is a 33.91 percent increase over losses of $(1.15) per share from the
Bionano Genomics (NASDAQ:BNGO) sees Q2 sales of $7.500 million-$7.800 million vs $7.520 million analyst estimate.
Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $30.000 million-$33.000 million to $30.000 million-$33.000 million vs $32.137 million estimate.
SAN DIEGO, May 13, 2026 -- Bionano Genomics, Inc. today reported financial results for the first quarter ended March 31, 2026. The Bionano business is healthy, with first quarter results...
Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics Inc: Bionano Genomics Inc - may offer and sell up to $400 million of securities - SEC filing...
$400,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsFrom time to time, we may offer and sell up to an aggregate amount of $400,000,000 of any combination of the securities described in this prospectus in
Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May 5, 2026. Dr. Luderer
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 48.7K | $56.98K | 0.00% | Added+31.6% | 2026-03-31 |
| FidelityFMR | fundamental | 6 | $7 | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.89 | — | — |
| 2026-05-13 | -0.88 | -0.76 | +13.64% |
| 2026-03-23 | -4.14 | -0.03 | +99.28% |
| 2025-11-13 | -2.34 | -1.59 | +32.05% |
| 2025-08-14 | -2.99 | -1.97 | +33.97% |
| 2025-05-14 | -3.02 | -1.15 | +61.96% |
| 2025-03-31 | -6.00 | -7.73 | -28.83% |
| 2024-11-14 | -9.60 | -16.05 | -67.19% |
| 2024-08-07 | -25.50 | -13.33 | +47.74% |
| 2024-05-08 | -38.70 | -30.48 | +21.24% |
| 2024-03-05 | -52.20 | -57.60 | -10.34% |
| 2023-11-08 | -56.60 | -60.49 | -6.87% |
| 2023-08-09 | -63.00 | -74.40 | -18.10% |
| 2023-05-09 | -62.00 | -72.00 | -16.13% |
| 2023-03-09 | -60.00 | -78.00 | -30.00% |
| 2022-11-03 | -68.00 | -66.00 | +2.94% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BNGO | +5.08% | +10.71% | -18.95% | -66.21% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.12% | +15.35% | -15.51% | -78.90% |